Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Researchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccine

Frontiers Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern

Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates

Second Boost of Omicron SARS-CoV-2 S1 Subunit Vaccine Induced Broad Humoral Immune Responses in Elderly Mice

Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine

Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity

PDF) Beta variant COVID-19 protein booster vaccines elicit durable cross- neutralization against SARS-CoV-2 variants of concern in non-human primates

Biomedicines, Free Full-Text

Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines